# Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

> **NCT02160574** · PHASE1 · COMPLETED · sponsor: **Zurex Pharma, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Surgical Site Infection

## Interventions

- **DRUG:** ChloraPrep
- **DRUG:** 0.1% Sodium Lauryl Sulfate
- **DRUG:** 0.9% Physiological Saline
- **OTHER:** ZuraPrep without IPA

## Key facts

- **NCT ID:** NCT02160574
- **Lead sponsor:** Zurex Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160574, "Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02160574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*